The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Open accessAbstract
BACKGROUND: Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis. METHODS: We randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body weight, at weeks 0, 4, and 16). The primary end point was a 90% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12. RESULTS: At week 12, the percentage of patients with a 90% or greater reduction in the PASI score was 77% (64 of 83 patients) for risankizumab (90-mg and 180-mg groups, pooled), as compared with 40% (16 of 40 patients) for ustekinumab (P<0.001); the percentage of patients with a 100% reduction in the PASI score was 45% in the pooled 90-mg and 180-mg risankizumab groups, as compared with 18% in the ustekinumab group. Efficacy was generally maintained up to 20 weeks after the final dose of 90 or 180 mg of risankizumab. In the 18-mg and 90-mg risankizumab groups and the ustekinumab group, 5 patients (12%), 6 patients (15%), and 3 patients (8%), respectively, had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adverse event; there were no serious adverse events in the 180-mg risankizumab group. CONCLUSIONS: In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was associated with clinical responses superior to those associated with ustekinumab. This trial was not large enough or of long enough duration to draw conclusions about safety. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT02054481 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Parisi, R., Symmons, D. P. M., Griffiths, C. E. M., & Ashcroft, D. M. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.339 · Cited by 2,592
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Self-citationThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Self-citationVolpe, E., Servant, N., Zollinger, R., Bogiatzi, S. I., Hupé, P., Barillot, E., & Soumelis, V. (2008) · Nature Immunology · doi:10.1038/ni.1613 · Cited by 938
Stern, R. S., Nijsten, T., Feldman, S. R., Margolis, D. J., & Rolstad, T. (2004) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2003.09102.x · Cited by 732
Langan, S. M., Seminara, N. M., Shin, D. B., Troxel, A. B., Kimmel, S. E., Mehta, N. N., Margolis, D. J., & Gelfand, J. M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.365 · Cited by 525
Papp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
Self-citationLi, B., Tsoi, L. C., Swindell, W. R., Gudjonsson, J. E., Tejasvi, T., Johnston, A., Ding, J., Stuart, P. E., Xing, X., Kochkodan, J. J., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.28 · Cited by 397
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306
Papp, K., Thaçi, D., Reich, K., Riedl, E., Langley, R. G., Krueger, J. G., Gottlieb, A. B., Nakagawa, H., Bowman, E. P., Mehta, A., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13932 · Cited by 276
Self-citationLangley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Krueger, J. G., Ferris, L. K., Menter, A., Wagner, F., White, A., Visvanathan, S., Lalovic, B., Aslanyan, S., Wang, E. E. L., Hall, D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.018 · Cited by 256
Self-citationCutting Edge: A Critical Functional Role for IL-23 in Psoriasis
Tonel, G., Conrad, C., Laggner, U., Di Meglio, P., Grys, K., McClanahan, T. K., Blumenschein, W. M., Qin, J.-Z., Xin, H., Oldham, E., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001538 · Cited by 224
WOODWORTH, T. G., Furst, D. E., Alten, R., et al. (2007) · PubMed · Cited by 112
Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis
Weisman, S. M., Pollack, C., & Gottschalk, R. (2003) · Journal of Dermatological Treatment · doi:10.1080/09546630310013360 · Cited by 82
The impact of psoriasis on 10-year Framingham risk
Mehta, N. N., Krishnamoorthy, P. M., Yu, Y., Khan, O., Raper, A. C., Voorhees, A. V., Troxel, A. B., & Gelfand, J. M. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.05.016 · Cited by 59
Cited by
Psoriasis Pathogenesis and Treatment
Rendon, A., & Schäkel, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061475 · Cited by 2,064
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Self-citationJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationThe Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Self-citationGordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31713-6 · Cited by 678
Self-citation
Metadata
- Authors
- Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J.-P., Menter, A., Philipp, S., Sofen, H., Tyring, S., Berner, B. R., Visvanathan, S., Pamulapati, C., Bennett, N., Flack, M., Scholl, P., & Padula, S. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-20
- Volume
- 376
- Issue
- 16
- Pages
- 1551-1560
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606035821
- Cited by
- 514
- References
- 20
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.